UroGen Pharma, Inc. news
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today announced the first published report of real-world experience utilizing the antegrade approach for Jelmyto® (mitomycin) for pyelocalyceal solution administration in the Journal of Urology online on February 7, 2022. This report provides a stepwise treatment approach to low-grade Upper Tract Urothelial Cancer (LG
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced the initiation of its Phase 3 ENVISION study of UGN-102 (mitomycin) for intravesical solution, in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC).
ENVISION is a single-arm, multinational, multicenter study evaluating the efficacy and safety of UGN-102 as primary c
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following virtual healthcare conferences in January:
40th Annual J.P. Morgan Healthcare Conference
- Thursday, January 13 at 9:45 a.m. ET
HC Wainwright BioConnect Conference
- Presentation available
- Study explores opportunity to shift from clinic to home instillation of this promising non-surgical treatment
- Potential to transform care and access to treatment for this growing patient population
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that the first patient has received their fir
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that the Company has entered into a strategic funding agreement with RTW Investments, LP and its affiliated entities (“RTW”).
Under the terms of the agreement, subject to customary closing conditions, UroGen will receive $75 million in upfront cash from RTW in re